

pSELECT-zeo-HSV1tk

A plasmid encoding a CpG-free HSV1tk

Catalog code: psetz-hsv1tk

For research use only

Version 20L01-MM-02

PRODUCT INFORMATION

Content:

- 20 µg of pSELECT-zeo-HSV1tk plasmid provided as lyophilized DNA
- 1 ml of Zeocin™ (100 mg/ml)

Storage and Stability:

Product is shipped at room temperature.
Lyophilized DNA should be resuspended upon receipt and stored at -20 °C.
Resuspended DNA is stable more than one year at -20 °C.
Store Zeocin™ at 4 °C or at -20 °C. The expiry date is specified on the product label.

Quality control:

Plasmid construct has been confirmed by restriction analysis and sequencing. Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

pSELECT-zeo plasmids contain genes that have been chemically synthesised. The DNA sequence of these genes was modified by optimizing the codon usage, reducing or eliminating the CpG motifs, and avoiding secondary DNA structures, without changing the amino acid sequence of the wild type proteins.

pSELECT-zeo plasmids may be used:

To subclone the synthetic gene into another vector: To facilitate subcloning, the HSV1tk gene is flanked by two unique restriction sites: Nco I at the 5' end that encompasses the start codon, and Nhe I at the 3' end.

To express the synthetic gene in mammalian cells: pSelect-zeo is a mammalian expression plasmid selectable in *E. coli* and mammalian cells with Zeocin™, as the *Sh ble* gene in the second expression cassette is driven by the eukaryote CMV enhancer/promoter in tandem with the bacterial EM7 promoter.

PLASMID FEATURES

First expression cassette

- **hEF1-HTLV prom** is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter¹ and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat². The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.
- **HSV1tk CpG-free:** The Herpes Simplex Virus 1 (HSV1) thymidine kinase gene, engineered to contain no CpG motif.
- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA³.
- **ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

Second expression cassette

- **CMV enh/prom:** The human cytomegalovirus immediate-early gene 1 promoter/enhancer was originally isolated from the Towne strain and was found to be stronger than any other viral promoters.
- **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.
- **Zeo:** Resistance to Zeocin™ is conferred by the *Sh ble* gene from *Streptoalloteichus hindustanus*. The *Sh ble* gene is driven by the CMV enhancer/promoter in tandem with the bacterial EM7 promoter allowing selection in both mammalian cells and *E. coli*.
- **βGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription⁴.

METHODS

Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H₂O. Store resuspended plasmid at -20 °C.

Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or in other commonly used laboratory *E. coli* strains, such as DH5α.

Zeocin™ usage

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media and at 50-200 µg/ml to select Zeocin™-resistant mammalian cells.

References:

1. Kim, D.W. *et al.* (1990). *Gene* 2: 217-223.
2. Takebe, Y. *et al.* (1988). *Mol. Cell Biol.* 1: 466-472.
3. Carswell, S., and Alwine, J.C. (1989). *Mol. Cell Biol.* 10: 4248-4258.
4. Yu J & Russell JE. (2001). *Mol Cell Biol*, 21(17):5879-88.

TECHNICAL SUPPORT


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com



PvuI (7)
SgfI (6)

1 GGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCGAGCGCACATCGCCACAGTCCCCGAGAAGTTGGGGGAGGGTGGCAATTGAACGGTGCCTA

101 GAGAAGGTGGCGGGGTAACCTGGGAAAGTGTGCTGTACTGGCTCCGCCTTTTCCCGAGGGTGGGGGAGAACCCTATATAAGTGCAGTAGTCGCC

HindIII (245)
Psp1406I (203)

201 GTGAACGTTCTTTTTCGCAACGGGTTTCCGCCAGAACACAGTGAAGCTTCGAGGGCTCGCATCTCTCTTACAGCGCCCGCCCTACCTGAGGCC

301 GCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCTCCCGCTGTGGTGCTTCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACC

401 GGGCCTTTGTCCGGCGCTCCCTTGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCTGACCTGCTTCTCAACTCTACGCTTTTGTTCGTTT

NcoI (560)
BstEII (555)
KasI (535)

501 TCTGTTCTGCGCGGTTACAGATCCAAGCTGTGACCGCGCCTACCTGAGATCAccggtcacCATGGCTTCTTACCCTGGACACCAGCATGCTTCTGCCTT

1 M A S Y P G H Q H A S A F

BbsI (656)
StuI (682)**BstAPI (690)**

601 TGACCAGGCTGCCAGATCCAGGGGCCACTCCAACAGGAGAAGTGCCTAAGACCCAGAAAGACAGCAGGAAGCCACTGAGGTGAGGCTGAGCAGAAGATG

13 D Q A A R S R G H S N R R T A L R P R R Q Q E A T E V R P E Q K M

BsrGI (716)

701 CCAACCTGTGAGGGTGTACATTGATGGACCTCATGGCATGGGCAAGACCACCACCCTCAACTGCTGGTGGCACTGGGCTCCAGGGATGACATTGTGT

47 P T L L R V Y I D G P H G M G K T T T T Q L L V A L G S R D D I V

801 ATGTGCCTGAGCCAATGACCTACTGGAGAGTGTAGGAGCCTCTGAGACCATTGCCAACATCTACACCACCCAGCACAGGCTGGACCAGGGAGAAATCTC

80 Y V P E P M T Y W R V L G A S E T I A N I Y T T Q H R L D Q G E I S

901 TGCTGGAGATGCTGCTGTGGTGTGACCTCTGCCAGATCACAATGGGAATGCCTATGCTGTGACTGATGCTTCTGGCTCCTCACATTGGAGGAGAG

113 A G D A A V V M T S A Q I T M G M P Y A V T D A V L A P H I G G E

Acc65I (1088)

1001 GCTGGCTCTTCTCATGCCCTCCACCTGCCCTGACCTGATCTTTGACAGACACCCCATTCGACGCCCTGCTGTGCTACCCAGCAGCAAGGTACCTCATGG

147 A G S S H A P P P A L T L I F D R H P I A A L L C Y P A A R Y L M

BbsI (1189)

1101 GCTCCATGACCCACAGGCTGTGCTGGCTTTTGTGGCCCTGATCCCTCAACCTCCCTGGCACCACATTGTTCTGGGAGCACTGCCTGAAGACAGACA

180 G S M T P Q A V L A F V A L I P P T L P G T N I V L G A L P E D R H

1201 CATTGACAGGCTGGCAAAGAGGAGAGACTGGAGAGAGACTGGACCTGGCCATGCTGGCTGCAATCAGAAGGGTGTATGGACTGCTGGCAAACACTGTG

213 I D R L A K R Q R P G E R L D L A M L A A I R R V Y G L L A N T V

1301 AGATACCTCCAGTGTGGAGGCTCTTGGAGAGAGGACTGGGACAGCTCTTGGAAACAGCAGTCCCCCTCAAGGAGCTGAGCCCACTGCAATGCTGGTC

247 R Y L Q C G G S W R E D W G Q L S G T A V P P Q G A E P Q S N A G

BsrGI (1472)

1401 CAAGACCCACATTGGGGACACCCTGTTACCCTGTTCCAGAGCCCTGAGCTGCTGGCTCCCAATGGAGACCTGTACAATGTGTTTGCCTGGGCTCTGGA

280 P R P H I G D T L F T L F R A P E L L A P N G D L Y N V F A W A L D

Ppu10I (1525)
NsiI (1525)

1501 TGTTCTAGCCAAGAGGCTGAGGTCCATGCATGTGTTTCCTGGACTATGACCAGTCCCTGCTGGATGCAGAGATGCTCTGCTGCAACTAACCTCTGGC

313 V L A K R L R S M H V F I L D Y D Q S P A G C R D A L L Q L T S G

BstXI (1667)

1601 ATGGTGCAGACCCATGTGACCACCCTGGCAGCATCCCACCATCTGTGACCTAGCCAGAACCTTGGCAGGAGATGGGAGAGGCAACTAAACCTGAG

347 M V Q T H V T T P G S I P T I C D L A R T F A R E M G E A N •

1701 CTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAACCACAACCTAGAATGCAGTGAAAAAATGCTTTATTTGTGAAATTTGTGATGCTAT

HpaI (1837) **MfeI (1848)**

1801 TGCTTTATTTGTAACATTATAAGCTGCAATAAACAAGTTAAACAACAATTGCATTCAATTTATGTTTCAGGTTTCAGGGGAGGTGTGGGAGTTTTT

EcoRI (1933)

1901 TAAAGCAAGTAAACCTCTACAAATGTGGTATGGAATTTCTAAAATACAGCATAGCAAACTTTAACCTCCAAATCAAGCCTCTACTTGAATCCTTTTCTG

AlwNI (2023)

2001 AGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAATGTGCATTAGCTGTTTGCAGCCTCACCTTCTTTCATGGAGTTTAAAGATATAGTGTATTTTC

SspI (2172) **SwaI (2186)**

2101 CCAAGGTTTGAACCTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCACATTCCCTTTTTAGTAAAATATTCAGAAATAATTTAAATACATCA

EcoO109I (2247)

2201 TTGCAATGAAAATAAATGTTTTTATTAGGCAGAAATCCAGATGCTCAAGGCCCTTCATAATATCCCCAGTTTAGTAGTTGGACTTAGGGAACAAAGGAA

DraIII (2365) **EagI (2385)**

2301 CCTTTAATAGAAATTGGACAGCAAGAAAGCGAGCTTCTAGCTTATCCTCAGTCTGCTCTCTGCCACAAAGTGCACGAGTTGCCGGCCGGTGCAGCA

125 D Q E E A V F H V C N G A P D R L

2401 GGGCGAATCCCGCCCCACGGCTGCTGCGGATCTCGGTCTAGGCTGCGGAGGCGTCCCGGAAGTTTCGGTGGACACGACCTCCGACCACTCGCGGTA

107 A F E R G W P Q E G I E T M A P G S A D R F N T S V V E S W E A Y

2501 CAGCTCGTCCAGGCGCGCACCCACACCAGGCCAGGTTGTTGTCGGCACCACTGGTCTGGACCGCGCTGATGAACAGGGTACGTCGTCGGGACC

74 L E D L G R V W V W A L T N D P V V Q D Q V A S I F L T V D D R V

SgrAI (2601) XmaI (2628) BsrBI (2664) BssHII (2680)
 2601 ACACCGGCGAAGTCGCTCCACGAAGTCCCGGAGAACCCGAGCCGGTCCGAGTCCAGAACTCGACCGCTCCGGCGACGTCGCGCGGGTGAGCACCGGAA
 40 V G A F D D E V F D R S F G L R D T W F E V A G A V D R A T L V P V
 SfiI (2716) AseI (2776)
 2701 GGGCACTGGTCAACTTGGCCATGATGGCCCTCTATAGTGAGTCTATTATACTATGCCGATATACTATGCCGATGATTAATTGTCAAACACAGCGTGGAT
 7 A S T L K A M
 SacI (2833)
 2801 GGGCTCTCCAGCTTATCTGACGGTTCATAAACGAGCTCTGCTTATATAGACCTCCACCGTACACGCCTACCGCCATTTGCGTCAATGGGCGGGAGTT
 SpeI (2931)
 2901 GTTACGACATTTTGAAAGTCCCGTTGATTTACTAGTCAAAACAAACTCCCATTGACGTCAATGGGGTGGAGACTTGAAATCCCCGTGAGTCAAACCGC
 SnaBI (3059)
 3001 TATCCACGCCATTGATGTACTGCCAAAACCGCATCAICATGGTAATAGCGATGACTAATACGTAGATGTACTGCCAAGTAGGAAAGTCCATAAGGTCA
 NdeI (3164)
 3101 TGACTGGGCATAATGCCAGGCGGGCCATTTACCGTCATTGACGTCAATAGGGGGCGTACTTGGCATATGATACACTTGATGTACTGCCAAGTGGGCAGT
 3201 TTACCGTAAATACTCCACCCATTGACGTCAATGAAAGTCCCTATTGGCGTACTATGGGAACATACGTCATTATTGACGTCAATGGGCGGGGTCTGTTG
 PacI (3350)
 PstI (3343) SdaI (3342) BspLU11I (3360)
 3301 GCGGTCAGCCAGGCGGGCCATTTACCGTAAGTTATGTAACGCCTGCAGGTTAATTAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAA
 3401 AAAGCCCGCTTGTGGGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTA
 3501 TAAAGATACCAGGCTTTCCCTGGAAGCTCCCTCGTGGCTCTCCTGTTCCGACCCTGCCGTTACCGGATACCTGTCGCTTTTCTCCCTCGGGAA
 ApaLI (3674)
 3601 GCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGTTCCGCTCCAAGCTGGGCTGTGTGCACGAACCCCGTTCAGCCCGA
 AlwNI (3771)
 3701 CCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCG
 3801 AGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTA
 3901 CCTTCGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGGTTCGAAGCAGCAGATTACGCGCAGAAAAA
 PacI (4090) SmaI
 4001 AGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGTCTGACGCTCAGTGGAAACGAAAACCTCACGTTAAGGGATTTTGGTCAATGGCTAGTTAATTAACA
 EagI (4110) NotI (4109)
 4101 TTTAAATCAGCGCCGCAATAAAATATCTTTATTTTATTACATCTGTGTGGTTTTTTTGTGTGAATCGTAACTAACATACGCTCTCCATCAAACAA
 4201 AACGAAACAAAACAACTAGCAAATAGGCTGTCCCAGTGCAAGTGCAGGTGCCAGAACATTTCTCTATCGAA